HSDT - Helius Medical Technologies Inc. Receives Letter of Intent from the Québec Ministry of Health and Social Services to Purchase 30 PoNS® Devices | Benzinga
-- PoNS® devices to be provided to a least five sites in five separate administrative regions within Québec --
-- Government-funded initiative will evaluate the benefits of PoNS Therapy™ when used by patients who have suffered the effects of stroke --
NEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it has received a letter of intent ("LOI") from the Québec Ministry of Health and Social Services ("MSSS") for the purchase of 30 Portable Neuromodulation Stimulator ("PoNS®") devices as part of an initiative to assess the value of using PoNS to treat patients suffering symptoms due to stroke.
"Clinical evidence shows that stroke patients treated with PoNS experience significant improvement in gait and balance as well as a reduced risk of falling," said Dane Andreeff, Helius' President and Chief Executive Officer. "We are grateful that a second important Canadian healthcare provider has recognized the potential benefits of PoNS Therapy. A few weeks ago, the University of Montreal placed an order for ten PoNS devices to be used in a research study assessing stroke recovery, and the MSSS's initiative will allow 30 more patients to benefit from PoNS Therapy through MSSS's funding. We believe this order will accelerate adoption in Canada and, importantly, provide invaluable therapeutic evidence to support Helius' ongoing efforts to receive authorization for stroke in the United States."
The sales of these PoNS devices are expected to commence in the fourth quarter of 2023 and extend through the first quarter of 2024.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator. For more information visit www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator ("PoNS") is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a ...